Millennium Development Goals (MDGs) (ab) exercise global leadership in galvanising international action to deliver on the MDG pledges in view of the growing evidence that the world is falling far short of the promises made in relation to the MDGs; (ac) support the "MDG gap task force" initiative to monitor global commitments on aid, trade, debt relief and access to essential medicines and technology; (ad) call for the urgent organisation of the high-level UN conference on the world financial and economic crisis and its impact on development, which was agreed at the 2008 Doha Financing for Development conference; (ae) pursue discussion ...[+++] of the Business Call to Action initiative and the commitments to funding and supporting MDG efforts, including how this could be matched by an increase in accountability from the corporate sector; (af) advocate, in tandem with all these initiatives, signing up to the principles enshrined in the Paris Declaration on Aid Effectiveness, and to the Accra Agenda for Action, in order to improve the quality and delivery of aid; (ag) use the occasion of the 64th UNGA to report on the progress made towards meeting the benchmarks set out in the EU Agenda for Action on MDGs; (ah) invite the Commission to report on the progress made in implementing MDG contracts and encourage other donors to deliver more of their aid on a long-term, predictable basis in the form of budget support;

Millennium Development Goals (MDGs) (ab) exercise global leadership in galvanising international action to deliver on the MDG pledges in view of the growing evidence that the world is falling far short of the promises made in relation to the MDGs; (ac) support the "MDG gap task force" initiative to monitor global commitments on aid, trade, debt relief and access to essential medicines and technology; (ad) call for the urgent organisation of the high-level UN conference on the world financial and economic crisis and its impact on development, which was agreed at the 2008 Doha Financing for Development conference; (ae) pursue discussion ...[+++] of the Business Call to Action initiative and the commitments to funding and supporting MDG efforts, including how this could be matched by an increase in accountability from the corporate sector; (af) advocate, in tandem with all these initiatives, signing up to the principles enshrined in the Paris Declaration on Aid Effectiveness, and to the Accra Agenda for Action, in order to improve the quality and delivery of aid; (ag) use the occasion of the 64th UNGA to report on the progress made towards meeting the benchmarks set out in the EU Agenda for Action on MDGs; (ah) invite the Commission to report on the progress made in implementing MDG contracts and encourage other donors to deliver more of their aid on a long-term, predictable basis in the form of budget support;

This partnership is intended to enable ACP countries to render more effective their legislation and quality assurance systems for medicines, and to improve aspects such as their controls, their action against substandard or counterfeit medicines and their information management.

This partnership is intended to enable ACP countries to render more effective their legislation and quality assurance systems for medicines, and to improve aspects such as their controls, their action against substandard or counterfeit medicines and their information management.

Although we wish to highlight the declaration of the UN General Assembly Special Session of 2 June 2006, in particular its references to promoting access to medicines for all, which includes production of generic antiretroviral drugs and other essential drugs for AIDS-related infections, it is regrettable that the declaration lacks any global targets or timelines on treatment, resources and prevention, and does not provide a viable action plan to back up the goal of providing universal access for all HIV-affected people by 2010 .

The general sections of this Annex give the requirements for all categories of medicinal products; they are supplemented by sections containing additional special requirements for radiopharmaceuticals and for biological medicinal products, such as vaccines, serums, toxins, allergen products, medicinal products derived from human blood or plasma.